do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline Can dipeptidyl peptidase‑4 (DPP‑4) inhibitors be combined semaglutide ( GLP‑1 agonist)? Frontiers | Mechanisms of action
Description
So, what does this suggest for the future of obesity treatment
8 Thus, it fosters reduction in appetite, food quantity and calorie intake
JAMA Cardiol 10(1):9698 [DOI] [PMC free article] [PubMed] [Google Scholar] 21.Haddy N, Jourdain H, Desplas D, Bertrand M, Jabagi MJ, Rives-Lange C, Zureik M (2025) Use of semaglutide (Wegovy) in adults in France: A nationwide drug utilization study
Lankisch, P
In 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a mean 39.8-month follow-up
Jardine, R
